Ipsen: Dysport authorisation extended in UK

(CercleFinance.com) - Ipsen announces that the MHRA in the UK has extended the authorisation for Dysport for symptomatic treatment of upper limb spasticity in children with cerebral palsy, aged two years and over.


This authorisation follows the phase III study which demonstrated that Dysport reduces the symptoms of spasticity in children aged two years and over, according to the Modified Ashworth Scale (MAS). No new security concerns have been identified.

"An estimated 1 in 400 babies born with cerebral palsy in the UK, 75-91% of whom will have a specific type known as spastic cerebral palsy," Ipsen said.


Copyright (c) 2020 CercleFinance.com. All rights reserved.